TY  - JOUR
TI  - The effect of visfatin rs2110385 gene polymorphism over
oral antidiabetic drug response 
AB  - Aim: The aim of our study is to investigate the effects of rs2110385 polymorphism of the visfatin gene on obesity in Turkish study
groups. The rs2110385 polymorphism was analyzed in terms of genotype frequencies, obesity-related parameters, demographic
data, serum visfat-in levels and drug use in obese and non-obese subjects.
Materials and Methods: The PCR-RFLP method was used to determine the visfatin gene rs2110385 genotype. MicroELISA method
was used to measure serum visfatin levels.
Results: Homozygous wild type (G / G), heterozygous (G / T) and homozygous polymor-phic (T / T) genotype frequencies of the
visfatin gene rs2110385 polymorphism was found to be respectively as, 54.1%, 66.7%, 61.8% in obese and 45.9%, 33.3%, 38.2% in
non-obese. There was no statistical difference between the groups in terms of genotype frequen-cies and serum visfatin levels.
Homozygous wild type genotype frequency was higher than heterozygous and homozygous polymorphic genotype in obese
group with type 2 diabetes mellitus using sulfonylurea and glinide, respectively. The rs2110385 mutation reduced the response to
antidiabetics in obese patients with type 2 diabetes mellitus.
Conclusions: In conclusion, our results may indicate that obese type 2 diabetic patients with the visfatin gene T / T rs2110385
genotype may benefit more efficiently from oral an-tidiabetic drugs other than glinide or sulfonylurea.
AU  - Koldemir Gunduz, Meliha
AU  - ÇAGATAY, PENBE
AU  - SUSLEYICI, Belgin
AU  - KAYHAN, Figen Esin
AU  - TASKIN, MUSTAFA
DO  - 10.5455/annalsmedres.2021.02.129
PY  - 2021
JO  - Annals of Medical Research
VL  - 28
IS  - 12
SN  - 2636-7688
SP  - 2134
EP  - 2139
DB  - TRDizin
UR  - http://search/yayin/detay/514588
ER  -